Mezagitamab for Kidney Transplant Rejection
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests a new medicine called mezagitamab for people whose kidney transplant is being rejected by their immune system more than 6 months after transplant. The drug may help prevent further kidney damage and preserve your transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–80 years
- Kidney biopsy within the last 30 days showing antibody-mediated rejection (AMR) that started more than 6 months after transplant
- Kidney function (eGFR) greater than 30 mL/min/1.73m²
- Blood test showing donor-specific antibodies (immune proteins attacking the transplant)
- Cannot have received certain rejection treatments (anti-CD38 therapy, complement inhibitors, rituximab) recently
- No active infections (hepatitis, HIV, tuberculosis) or serious infections in the past 2 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This study tests a new medicine called SG301 to see if it can safely treat antibody-mediated rejection (a type of kidney rejection) in people who have had a kidney transplant. It may help stop the immune system from attacking the transplanted kidney.
This trial tests a new two-step treatment for a type of long-term kidney rejection (chronic active antibody-mediated rejection) in transplant recipients. First, you receive an infusion of CD38 antibodies to clear harmful cells, then a months-long course of azathioprine pills to maintain the benefit and protect your kidney.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
This trial tests a new drug called mezagitamab for adults with IgA nephropathy, a kidney condition. The study aims to see if this drug can help reduce protein in the urine and preserve kidney function. You may be eligible if your kidney function is above a certain level and your urine protein is high enough.
Hear when a new Antibody-Mediated Rejection (AMR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.